Gain Therapeutics, Inc.

GANX Healthcare Biotechnology

Gain Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $55,200.00, down 60.6% from fiscal 2022. In the quarter to June 2026, EPS grew 42.1%, free cash flow grew 8.22% and total debt fell 23.9%, each against the same quarter a year earlier.

1.26 0.07 −5.26%
Market cap
$58.1M
P/E
0.0×
Fwd P/E
−2.4×
Dividend yield
—
F-score
1/9
Altman Z
−1.79
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
3.81 4.26 6.22 2.11
Current Ratio
4.36 4.69 6.63 2.52
Net Debt/EBITDA
2.74 3.03 4.61 1.76
Debt/Assets
2.23% 1.99% 1.76% 3.87%
Debt/Equity
0.03 0.03 0.02 0.07
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
1.00 0.84 1.02 0.93
Capex/Depreciation
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.11) (0.11) (0.14) (0.14)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.11) (0.11) (0.14) (0.14)
Cash per Share
0.31 0.39 0.63 0.25
Shareholders Equity per Share
0.26 0.33 0.56 0.17
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.26 0.33 0.56 0.17
Free Cash Flow
(4.68) (4.73) (4.62) (4.93)
Working Capital
11.54 14.34 18.88 6.35
Net Current Asset Value
10.84 13.49 17.98 5.46
Other line items
Average Payables
1.97 1.83 0.89 1.34
Average Assets
12.63 15.18 17.47 12.67
Average Common Equity
7.49 9.89 12.95 7.41

Fold the line items

Columns are period end dates